Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11779578 IRAK degraders and uses thereof

Patent 11779578 was granted and assigned to Kymera Therapeutics on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 11 Oct, 2023
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 11 Oct, 2023
Edits made to:
Infobox (+44 properties)
Article (+109 characters)
‌

 US Patent 11779578 IRAK degraders and uses thereof

Article

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Infobox
Is a
Patent
Patent
Patent Applicant
Kymera Therapeutics
Kymera Therapeutics
Current Assignee
Kymera Therapeutics
Kymera Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11779578
Patent Inventor Names
Matthew M. Weiss
Date of Patent
October 10, 2023
Patent Application Number
17125426
Date Filed
December 17, 2020
Patent Citations
‌
US Patent 7173015 Inhibition of Syk kinase expression
‌
US Patent 7208157 Proteolysis targeting chimeric pharmaceutical
‌
US Patent 7273920 Controlling protein levels in eucaryotic organisms
‌
US Patent 7307077 Heterocyclic compound and antitumor agent containing the same as effective ingredient
‌
US Patent 7390799 Apoptosis promoters
‌
US Patent 7402325 Supercritical carbon dioxide extract of pharmacologically active components from
‌
US Patent 7449458 Prodrugs of 2,4-pyrimidinediamine compounds and their uses
‌
US Patent 7501496 Anti-OX40L antibodies
‌
US Patent 7514444 Inhibitors of bruton's tyrosine kinase
‌
US Patent 7528143 Bi-aryl meta-pyrimidine inhibitors of kinases
‌
US Patent 7557210 2,4-pyrimidinediamine compounds and their uses
‌
US Patent 7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
‌
US Patent 7622496 Modified lysine-mimetic compounds
‌
US Patent 7667039 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors
‌
US Patent 7713943 Further use of protein kinase N beta
‌
US Patent 7781433 Pharmaceutical compounds
‌
US Patent 7932260 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
‌
US Patent 7989622 Phosphatidylinositol 3-kinase inhibitors and methods of their use
‌
US Patent 8138347 Quinoline derivatives as PI3 kinase inhibitors
‌
US Patent 8185616 Route designing method
‌
US Patent 8217035 Pyrimidine derivatives used as PI-3-kinase inhibitors
‌
US Patent 8338439 2,4-disubstituted pyrimidines useful as kinase inhibitors
‌
US Patent 8486941 Phenyl amino pyrimidine compounds and uses thereof
‌
US Patent 8906682 Methods for treatment of cancer
‌
US Patent 9500653 Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
‌
US Patent 9632089 Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
‌
US Patent 9694084 Methods to induce targeted protein degradation through bifunctional molecules
‌
US Patent 9750816 Methods to induce targeted protein degradation through bifunctional molecules
‌
US Patent 9770512 Methods to induce targeted protein degradation through bifunctional molecules
‌
US Patent 9821068 Methods to induce targeted protein degradation through bifunctional molecules
‌
US Patent 9969710 Heteroaryl compounds as IRAK inhibitors and uses thereof
‌
US Patent 10125114 Methods to induce targeted protein degradation through bifunctional molecules
‌
US Patent 10336744 1AP E3 ligase directed proteolysis targeting chimeric molecules
‌
US Patent 10874743 IRAK degraders and uses thereof
Patent Primary Examiner
‌
Zinna Northington Davis

Find more entities like US Patent 11779578 IRAK degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo